Long term prospective observational cohort study on the safety and efficacy of abatacept subcutaneus in the daily clinical practice of rheumatoid arthritis

Long term prospective observational cohort study on the safety and efficacy of abatacept subcutaneus in the daily clinical practice of rheumatoid arthritis - Abatacept subcutaneous in rheumatoid arthritis

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39013

Enrollment

100

Registered

2013-08-13

Start date

2013-09-18

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory rheumatic disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients * 18 years old at treatment initiation Patients informed and accepting to participate (Written informed consent) Patients diagnosed with established moderate to severe active RA as per the 1987 ACR criteria/2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria Patients who at their physician*s discretion are initiated with abatacept SC.

Exclusion criteria

Exclusion criteria: Patients currently participating in any interventional clinical trial in RA Contraindications against abatacept SC treatment.

Design outcomes

Primary

Measure	Time frame
Efficacy will be determined in comparison to baseline by measuring disease activity, radiological progression and functional capacity during follow-up. Safety will be determined by the occurrence of side effects.	—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results